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Abstract
Objectives:  To compare the role of alpha-blocker (Tamsulosin) monotherapy, anticholinergic (Tolterodine)
monotherapy or combination of both drugs versus  analgesics in improving post-ureteroscopy (URS) lower
urinary tract symptoms related to double-J ureteral stent.
Patients  and  methods:  Between January 2009 and June 2013, 160 consecutive patients with ureteric stones
were included in this study at 2 tertiary care centers’. Patients were randomized into 4 groups; group A
(n = 40) received 0.4 mg Tamsulosin once a day, group B (n  = 40) received 4 mg Tolterodine once a day,
group C (n  = 40) received Tamsulosin 0.4 mg and Tolterodine 4 mg once a day and group D (n  = 40) asebo once a day. All patients received analgesics on demand. Pre-treatment
y among-groups comparison after 14 days including ureteral stent symptom
y symptom index (USI), pain symptom index (PSI), general health index
PI), need for pain killer (PK), need for analgesia, visual analogue scale
ife (QOL)]. Side effects were recorded and compared.a control group, received plac
evaluation was done followed b
questionnaire (USSQ) [Urinar
(GHI), work perform index (W
(VAS) for pain and quality of l∗ Corresponding author.
-mail addresses: osmanco3247@yahoo.com (O. Abdelkader), kma02@fayoum.edu.eg (K. Mohyelden), mh sherief68@yahoo.com (M.H. Sherif),
ldaqados@yahoo.com (H. Aldaqadossi), ashelbaia@yahoo.com (A. Shelbaya), dr hosni@yahoo.com (H. Khairy), ahmedelnashar@gmail.com
A. Elnashar).
eer review under responsibility of Pan African Urological Surgeons’ Association.
ttp://dx.doi.org/10.1016/j.afju.2016.06.001
110-5704/© 2016 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Results:  Out of 160 patients, 153 patients (40, 38, 37 and 38 patients in groups A, B, C and D, respectively)
completed the study with a mean age of 34.3 ±  7.6 (20–50) years. All groups were comparable in terms of
age, gender, stone size and stone location, USSQ items and QOL. After 14 days, the USSQ and QOL were
significantly lower in group A, B and C in comparison with group D (p  < 0.05). Patients in group C had
significantly much improvement than those of groups A and B (p  < 0.05).
Conclusion:  Combination of alpha blockers (Tamsulosin) and Anticholinergics (Tolterodine) seems to
significantly improve post-URS lower urinary tract symptoms secondary to ureteral stents with lower need
for analgesia and better quality of life. Adverse effect of used drugs mentioned as transient and tolerated
by the patients without need for auxiliary medication.
© 2016 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(PSI), general health index (GHI), work performance index (WPI),Introduction
Ureteral stenting is a widespread procedure with variable indications
in urology, including post endoscopic procedures, prior to SWL in
selected cases, intolerable renal colic, and ureteral injury during
ureteroscopy [1].
However, ureteral stent placement might be associated by both-
ersome lower urinary tract symptoms (LUTS) including bladder
irritation, pain, frequency and dysuria. These symptoms usually
affect the patient’s quality of life and consequently the general health
and work [2]. Alpha adrenergic blockers have been widely used
to manage such stent related symptoms with encouraging results
[3,4].
Similarly, anticholinergics alone or in combination with -blockers
have been used successfully to treat LUTS related symptoms
associated with benign prostate hyperplasia (BPH) and overactive
bladder (OAB) syndrome [5,6]. These latter pathologies usually pre-
sented by LUTS/storage symptoms which mimic that of the stent
placement. Moreover, there are sparse of literature with level-1
evidence which compare the outcomes of these drugs, monother-
apy or in combination, in the management of those bothersome
symptoms.
Therefore, the aim of the present study was to evaluate the effi-
cacy and safety of Tamsulosin and Tolterodine, either monotherapies
or in combination, for improving LUTS/storage bladder symptoms
secondary to post-ureteroscopy (URS) double-J ureteral stenting.
A great effort has been done by Joshi et al. [7] to develop USSQ as
psychometrically valid measure to evaluate the stent related symp-
toms and QOL. USSQ explores six areas (sections) containing 38
items, the answers of which are based on a rating scale from 0 to
5 and the scoring system consists of a simple sum of the scores of
individual questions in each section. Those sections include (Uri-
nary symptom index, pain symptom index, general health index,
work performance index, sexual matter and additional problem
index) which contain 11, 8, 6, 7, 1 and 5 items, respectively. This
USSQ is considered the as the first valid objective tool to eval-
uate stent related symptoms and their effect on QOL. Following
this score, different versions has been published in Italian, Korean,
Spanish and Turkish language. Recently, the validated Arabic ver-
sion of the USSQ was introduced by El-Nehas et al. [8] that can
be used to evaluate the stent related symptoms and QOL in Arabic
patient.
n
oatients  and  methods
fter institutional board approval of the study protocol, 160 patients
ho underwent URS for management of ureteric stones were
ncluded after giving an informed consent to participate in the study.
efore URS, all patients were evaluated by history taking, clini-
al examination, laboratory investigations and radiological imaging
ncluding intravenous urography (IVU) and non-contrast spiral com-
uter tomography (CT).
atients between 20 and 50 years old (to avoid LUTS due to BPH),
ho had been managed for a single ureteral stone less than 10 mm
n their longest diameter, were included in the current randomized
ohort study. Patients with complicated URS, concurrent urinary
ract infection (UTI), ongoing medication with alpha blockers, anti-
holinergics or chronic analgesics, bilateral ureteric stents, open
reteral surgery, previous pelvic or prostatic surgery, pregnancy or
leeding disorders were excluded from the study.
rocedure
reteroscopic lithotripsy using pneumatic lithotripter with removal
f the stones was performed in all patients and double J ureteric
tent, (consisting from polyurethane), 6 F, 26–28 cm (according to
reter length) polyurethane material was inserted for 2 weeks post-
peratively. The ureteral stent symptom questionnaire (USSQ) was
sed to evaluate lower urinary tract symptoms and impact on quality
f life of ureteral stents. The patients were prospectively random-
zed into four groups using a computer software; group A (n  = 40)
eceived 0.4 mg Tamsulosin once a day, group B (n  = 40) received
 mg Tolterodine once a day, group C (n  = 40) received Tamsulosin
.4 mg and Tolterodine 4 mg once a day and group D (n  = 40) as a
ontrol group, received placebo once a day. All patients received
ain killer on demand.
he patients used Diclofenac potassium Tab. 50 mg when needed
up to twice per day), and paracetamol Tab. 500 mg when needed as
nalgesic medication.
re-treatment evaluation was done followed by among-groups com-
arison after 14 days including ureteral stent symptom questionnaire
USSQ), using urinary symptom index (USI), pain symptom indexeed for pain killer (PK), visual analogue scale (VAS) and quality
f life (QOL). Side effects were recorded and compared.
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ollected data included patient’s age, sex, stone size, stone location
nd laterality. Follow up consisted of urine analysis, plain kidney,
reter and bladder (KUB) film after one week to evaluate stone-free
tatus and to confirm the position of the stents.
tatistical  analysis
ata analysis was done using the commercially available Sta-
istical Package for Social Sciences for Windows, version 20
SPSS, Chicago, IL). Descriptive data were presented in terms of
umbers, percentages, and means with standard deviations. Cat-
gorical variables were compared using Fisher exact test while
ontinuous variables were compared by the analysis of variance
ANOVA) test. A two-sided level of significance under 0.05 was
dopted.
esults
ut of 160 patients, 153 patients completed the study, whereas 40,
8, 37, 38 patients in groups A, B, C, D, respectively with a mean
ge of 34.3 ±  7.60 (20–50) years, including 87 (56.9%) males and
6 (43.1%) female. Demographic data and stone characteristics of
ll groups are presented in Table 1. All groups were comparable in
erms of age, gender, stone size and stone locations (Table 1).
atient’s symptoms after stent insertion included dysuria, urgency,
rge incontinence, loin pain, suprapubic pain, frequency, and/or noc-
uria. Similarly, patients of all groups were comparable in terms of
he baseline ureteral stent symptom questionnaire (USSQ), using
rinary symptom index (USI), pain symptom index (PSI), general
ealth index (GHI), work performance index (WPI), need for pain
iller (PK), visual analogue scale (VAS) and quality of life (QOL)
p  > 0.05) (Table 2).
fter 14 days of stent insertion evaluation based on USSQ items
AS and impact on QOL revealing symptom scores were signifi-
antly lower in group A, B and C in comparison with the control
roup, with much better improvement in group C in comparison
ith either group A or group B alone (P  value 0.011, 0.001, 0.001,
.005, 0.005, 0.001 and 0.001) (Table 2).
he mean analgesic tablets consumption was 11, 7, 12.3, 10.8 and
6.4 in group A, B, C, D, respectively, which was comparable in
he first two groups and significantly higher in group D and lower
n group C.
here was no statistical significant difference between group A and
roup B in improvement of symptoms scores at day 14.
t
b
s
o
Table  1  Patient’s characteristics.
Variable Group An = 40 Group B
Sex (Male:Female) 24/16 22/16 
Age (Mean) 32.2 ± 10 34.3 ± 9
Mean stone size (mm) 9.5 ± 2.2 9.5 ± 1.8
Stone location(Middle/lower) ureter 8/32 7/31 
Stent character
6 fr/26 cm 12 18 
6 fr/28 cm 18 20 
Sexual active (+/−) 30/10 24/14 O. Abdelkader et al.
n group A, three patients (7.5%) suffered from dizziness and two
atients (5%) had headache. In group B, 18.4% had dry mouth and
.2% had dizziness. In group C, dry mouth and headache were
eported in 13.5% and 2.7% of patients, respectively. Anejacula-
ion was reported in 25% in group A (10/40) and in 5.4% in group
 (2/37). Otherwise, no other adverse events were detected in all
roups (Table 3).
iscussion
ost-URS ureteral stents help in preventing ureteral obstruction
nd assisting stone passage [2]. However, those indwelling ureteral
tents are usually associated with bothersome symptoms such as
rgency, renal colic, suprapubic pain, incontinence and haematuria
9]. These symptoms might result from irritation of the trigone and
he high pressure transmitted to the renal pelvis during micturition
fter ureteral stenting or detrusor muscle spasm in and around the
ntramural ureter [10,11].
oreover, stent-related pain and urinary frequency might be related
o spasm of the lower ureter or local trigone sensitivity as [3] there-
ore, the idea beyond adding anticholinergics to the -blockers in
he current study was to relief the irritation of the trigone and to
ecrease the ureteral spasm and or local trigonal sensitivity caused
y the lower end of the ureteral stent.
n the current study, we prospectively evaluated the impact of -
drenergic blockers monotherapy or anticholinergic monotherapy
r in combination on the outcome of these post-URS stent-related
ymptoms.
everal studies have compared the efficacy of -adrenergic block-
rs with or without anticholinergics for improvement of stent-
elated LUTS and QOL [3,4,12,13]. Moreover, both Alfuzosin and
olterodine monotherapy had significantly improved lower urinary
ymptoms and pain related to double-J stent according to USSQ
uestionnaire [12].
owever, other studies found no improvement in LUTS except
ith phenazopyridine versus  control 2-days post-stenting [13]. In
he current cohort USI, PSI, GHI, WPS, PK, VAS and QOL were
omparable at baseline. However, after 14 days, these scores signif-
cantly changed in groups A, B, and C in comparison to the control
roup, indicating improvements of the post-stenting symptoms in
hese groups. This symptom improvement was better in group C
han either group A or B alone, indicating the superiority of com-
ination therapy over the monotherapy. The -adrenergic blockers
eem to improve the stent-related symptoms due to the similarity
f these symptoms to benign prostate hyperplasia (BPH)-related
n = 38 Group Cn = 37 Group Dn = 38 P value
19/18 22/16 0.885
.8 32.6 ± 9.2 31 ± 9.2 0.922
 9.6 ± 2.6 7.8 ± 1.1 0.141
10/27 8/30 0.816
21 17
116 21
26/11 30/8 0.456
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Table  2  Overall results of the study in 4 groups at days 0, 14.
A alpha blockers B anticholinergics C combined D control P value*
US1 Day 0 Median 22 22 21 21.5 0.011
IQR 4.75 4 3.75 3.5
Day 14 Median 23 23 21 25
IQR 5.75 6.75 2.75 6.5
PSI2 Day 0 Median 13.5 13 13.5 14 <0.001
IQR 1.75 1 1 2
Day 14 Median 18 19 15 20.5
IQR 1.75 2 2.75 3
GH3 Day 0 Median 14.5 14.5 14 14.5 <0.001
IQR 3.75 3 2 3.75
Day 14 Median 16 16 13 17.5
IQR 3.75 3.75 2.75 3.75
WPS4 Day 0 Median 12.5 12 12.5 12 0.005
IQR 3 4.5 3 3.5
Day 14 Median 11 11 9 11
IQR 2 1.75 1.75 2.75
PK5 Day 0 Median 1 1 1 1 0.005
IQR 0 1 0 0
Day 14 Median 2 3 1 7
IQR 1 1 0 1.75
VAS6 Day 0 Median 4 4 4 4 <0.001
IQR 1.75 1 1 2
Day 14 Median 2 3 2 2.5
IQR 1 1 1 2
QOL7 Day 0 Median 4 4 5 5 <0.001
IQR 0.75 1 1 1
Day 14 Median 3 3 1 4
IQR 2 1 1 1
USSQ8 Day 0 Median 72 72 71 72 <0.001
IQR 8 14.5 4.5 7
Day 14 Median 75 79 62 87.5
IQR 10 4 4.5 8.5
USSQ, ureteral stent symptom questionnaire; USI, urinary symptom index; PSI, pain symptom index; GHI, general health index; WPI, work performance
 of lif
t
o
A
a
3
(index; PK, need for pain killer; VAS, visual analogue scale; QOL, quality
LUTs caused by involuntary contraction of the detrusor muscle [3].
Moreover, the randomized controlled trials have proved the role of
-blockers in improvement of stent-related LUTS and supported
their use in routine clinical practice [7,14–16].
In addition, Lamb et al. have reported that alpha-blockers reduce
stent-related symptoms assessed by the ureteral stent symptoms
questionnaire (USSQ) [14].No significant difference was noted between groups A, B at day 14
in symptoms scores improvement. After 14-days, USSQ maintained
their significant improvement in groups A, B, and C in comparison
D
r
t
s
Table  3  Adverse effect.
Adverse effect Group A -blocker Group B Anticholinergic 
Dizziness 3 2 
Headache 2 0 
Dry mouth 0 7 
Anejaculation 10 0 e.
o that of the control group with evident effect in group C than the
ther monotherapy groups.
dverse effect of drugs used in our study mentioned as transient
nd tolerated by the patient without need for auxiliary medication
2 patients (21%) from total presented in group A, B and C by 15
10%), 9 (6%) and 8 (5%), respectively.espite being a prospective study, the current study is limited by the
elatively small sample size per each group, and short time of sten-
ing, also ESWL cases, post open surgery stenting, and permanent
tent in cases of (tumor or obstructive uropathy) were not included.
Group C combined Group D control P value
0 0 0.104
1 0 0.561
5 0 0.046
2 0 0.006
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ombination of -adrenergic blockers and anticholinergics seems to
ave a better efficacy than either drug as a monotherapy in improving
he lower post-URS stent-related symptoms and quality of life and
s associated with lower needs for analgesia. Adverse effect of used
rugs mentioned as transient and tolerated by the patients without
eed for auxiliary medication.
uthor’s  contribution
sman Abdel Kader shared in performing the procedures and
ollecting data and was responsible for the design and edits the
anuscript. Khaled Mohyelden shared in performing the proce-
ures and was responsible for the design and edits the manuscript.
ahmoud H. Sherif shared in performing the procedures and col-
ecting data and responsible for statistics and data analysis. Adel
. Metwally shared in performing the procedures and collecting
ata. Hussein Adbelhameed shared in performing the procedures
nd collecting data. Hosni Khairy was responsible for revising the
anuscript. Ahmed Shelbaya and Ahmed Elnashar were responsi-
le for interpretation of data.
thical  approval
thical committee of Faculty of Medicine Fayoum University
pproved the protocol of this study. Informed consent was obtained
n all cases.
onflicts  of  interest
he authors declared that there was no conflict of interest.
unding
one declared.
cknowledgment
o Dr. Keely and all member of USSQ: As he is the first one to
evelop and assess the USSQ by its satisfactory validity with good
valuative and discriminate properties.
he authors would like to thank Dr. Mohammed Aly Elkoushy for
is kind help in editing this manuscript.
[O. Abdelkader et al.
eferences
[1] Jeong H, Hwak C, Lee SE. Ureteric stenting after ureteroscopy for
ureteric stones: a prospective randomized study assessing symptoms
and complications. BJU Int 2004;93:173–80.
[2] Chew BH, Knudsen BE, Denstedt D. The use of stents in contemporary
urology. Curr Opin Urol 2004;14:111–5.
[3] Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A,
Varkarakis IM, et al. Is there is a role for alpha blockers in treating
double J stent related symptoms. Urology 2006;67:35–9.
[4] Damiano R, Autorino R, Desio M, Giacobbe A, Palumbo IM,
D’Armiento M, et al. Effect of tamsulosin in preventing ureteral stent
related morbidity: a prospective study. J Endourol 2008;22:651–6.
[5] Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T,
Guan Z, et al. Tolterodine and tamsulosin for treatment of men with
lower urinary tract symptoms and overactive bladder: a randomized
controlled trial. J Am Med Assoc 2006;296:2319–28.
[6] Chung DE, Te AE. Tolterodine extended-release for overactive bladder.
Expert Opin Pharmacother 2009;10:2181–94.
[7] Joshi HB, Newns N, Stainthorpe A, MacDonagh R, Keeley JRFX,
Timoney AG. Ureteral stent symptom questionnaire. Development
and validation of a multidimensional quality of lifemeasure. J Urol
2003;169:1060–4.
[8] El-Nahas AR, Elsaadany MM, Tharwat M, Mosbah AA, Metwally
H, Hawary A, et al. Validation of the Arabic linguistic version of the
ureteral stent symptoms questionnaire. Arab J Urol 2014:1–4.
[9] Clayman RV. Ureteric stenting after ureteroscopy for ureteric stones: a
prospective randomized study assessing symptoms and complications.
J Urol 2005;173(June (6)):2022.
10] Thomas R. Indwelling ureteral stents: impact of material and shape on
patient comfort. J Endourol 1993;7:137–40.
11] Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, et al.
Prospective randomized evaluation of periureteral botulinum toxin type
A injection for ureteral stent pain reduction. J Urol 2010;183:598.
12] Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended
release and alfuzosin for the treatment of double-J stent-related symp-
toms. J Endourol 2009;23:1913–7.
13] Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow
PK, et al. A prospective randomized double blind placebo controlled
comparison between extended release oxybutinin versus phenazopy-
ridine for management of ureteral stent related discomfort. Urology
2008:71–92.
14] Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-
analysis showing the beneficial effect of alpha-blockers on ureteric
stent discomfort. BJU Int 2011;108(11):1894–902.
15] Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P. Is there a role
for -blockers in ureteral stent related symptoms? A systematic review
and meta-analysis. J Urol 2011;186(September (3)):928–34.16] El-Nahas AR, El-Assmy AM, Shoma AM, Eraky I, El-Kenawy
MR, El-Kappany HA. Self-retaining ureteral stents: analysis of fac-
tors responsible for patient discomfort. J Endourol 2006;20(January
(1)):33–7.
